Renal Fibrosis Pipeline Highlights – 2017 – Research and Markets

Submit the press release

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the „Renal Fibrosis Pipeline Highlights – 2017” drug pipelines to their offering.

This report, Renal Fibrosis Pipeline Highlights – 2017, provides most up-to-date information on key pipeline products in the global Renal Fibrosis market. It covers emerging therapies for Renal Fibrosis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Renal Fibrosis pipeline products by clinical trial stages including both early and late stage development – phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Renal Fibrosis pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Renal Fibrosis pipeline products by the company.

Short-term Launch Highlights:

Find out which Renal Fibrosis pipeline products will be launched in the US and Ex-US till 2020.

Summary:

  • Renal Fibrosis phase 3 clinical trial pipeline products
  • Renal Fibrosis phase 2 clinical trial pipeline products
  • Renal Fibrosis phase 1 clinical trial pipeline products
  • Renal Fibrosis preclinical research pipeline products
  • Renal Fibrosis discovery stage pipeline products
  • Renal Fibrosis pipeline products short-term launch highlights

Key Topics Covered:

1. Renal Fibrosis Pipeline by Stages

2. Renal Fibrosis Pipeline by Drug Class

3. Renal Fibrosis Pipeline by Company

4. Renal Fibrosis Phase 3 Clinical Trial Insights

5. Renal Fibrosis Phase 2 Clinical Trial Insights

6. Renal Fibrosis Phase 1 Clinical Trial Insights

7. Renal Fibrosis Preclinical Research Insights

8. Renal Fibrosis Discovery Stage Insights

9. Appendix

10. Research Methodology

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/glg2x6/renal_fibrosis

Renal Fibrosis Pipeline Highlights – 2017 – Research and Markets

Submit the press release

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the „Renal Fibrosis Pipeline Highlights – 2017” drug pipelines to their offering.

This report, Renal Fibrosis Pipeline Highlights – 2017, provides most up-to-date information on key pipeline products in the global Renal Fibrosis market. It covers emerging therapies for Renal Fibrosis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Renal Fibrosis pipeline products by clinical trial stages including both early and late stage development – phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Renal Fibrosis pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Renal Fibrosis pipeline products by the company.

Short-term Launch Highlights:

Find out which Renal Fibrosis pipeline products will be launched in the US and Ex-US till 2020.

Summary:

  • Renal Fibrosis phase 3 clinical trial pipeline products
  • Renal Fibrosis phase 2 clinical trial pipeline products
  • Renal Fibrosis phase 1 clinical trial pipeline products
  • Renal Fibrosis preclinical research pipeline products
  • Renal Fibrosis discovery stage pipeline products
  • Renal Fibrosis pipeline products short-term launch highlights

Key Topics Covered:

1. Renal Fibrosis Pipeline by Stages

2. Renal Fibrosis Pipeline by Drug Class

3. Renal Fibrosis Pipeline by Company

4. Renal Fibrosis Phase 3 Clinical Trial Insights

5. Renal Fibrosis Phase 2 Clinical Trial Insights

6. Renal Fibrosis Phase 1 Clinical Trial Insights

7. Renal Fibrosis Preclinical Research Insights

8. Renal Fibrosis Discovery Stage Insights

9. Appendix

10. Research Methodology

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/glg2x6/renal_fibrosis

Renal Fibrosis Pipeline Highlights – 2017 – Research and Markets

Submit the press release

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the „Renal Fibrosis Pipeline Highlights – 2017” drug pipelines to their offering.

This report, Renal Fibrosis Pipeline Highlights – 2017, provides most up-to-date information on key pipeline products in the global Renal Fibrosis market. It covers emerging therapies for Renal Fibrosis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Renal Fibrosis pipeline products by clinical trial stages including both early and late stage development – phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Renal Fibrosis pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Renal Fibrosis pipeline products by the company.

Short-term Launch Highlights:

Find out which Renal Fibrosis pipeline products will be launched in the US and Ex-US till 2020.

Summary:

  • Renal Fibrosis phase 3 clinical trial pipeline products
  • Renal Fibrosis phase 2 clinical trial pipeline products
  • Renal Fibrosis phase 1 clinical trial pipeline products
  • Renal Fibrosis preclinical research pipeline products
  • Renal Fibrosis discovery stage pipeline products
  • Renal Fibrosis pipeline products short-term launch highlights

Key Topics Covered:

1. Renal Fibrosis Pipeline by Stages

2. Renal Fibrosis Pipeline by Drug Class

3. Renal Fibrosis Pipeline by Company

4. Renal Fibrosis Phase 3 Clinical Trial Insights

5. Renal Fibrosis Phase 2 Clinical Trial Insights

6. Renal Fibrosis Phase 1 Clinical Trial Insights

7. Renal Fibrosis Preclinical Research Insights

8. Renal Fibrosis Discovery Stage Insights

9. Appendix

10. Research Methodology

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/glg2x6/renal_fibrosis

Renal Fibrosis Pipeline Highlights – 2017 – Research and Markets

Submit the press release

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the „Renal Fibrosis Pipeline Highlights – 2017” drug pipelines to their offering.

This report, Renal Fibrosis Pipeline Highlights – 2017, provides most up-to-date information on key pipeline products in the global Renal Fibrosis market. It covers emerging therapies for Renal Fibrosis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Renal Fibrosis pipeline products by clinical trial stages including both early and late stage development – phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Renal Fibrosis pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Renal Fibrosis pipeline products by the company.

Short-term Launch Highlights:

Find out which Renal Fibrosis pipeline products will be launched in the US and Ex-US till 2020.

Summary:

  • Renal Fibrosis phase 3 clinical trial pipeline products
  • Renal Fibrosis phase 2 clinical trial pipeline products
  • Renal Fibrosis phase 1 clinical trial pipeline products
  • Renal Fibrosis preclinical research pipeline products
  • Renal Fibrosis discovery stage pipeline products
  • Renal Fibrosis pipeline products short-term launch highlights

Key Topics Covered:

1. Renal Fibrosis Pipeline by Stages

2. Renal Fibrosis Pipeline by Drug Class

3. Renal Fibrosis Pipeline by Company

4. Renal Fibrosis Phase 3 Clinical Trial Insights

5. Renal Fibrosis Phase 2 Clinical Trial Insights

6. Renal Fibrosis Phase 1 Clinical Trial Insights

7. Renal Fibrosis Preclinical Research Insights

8. Renal Fibrosis Discovery Stage Insights

9. Appendix

10. Research Methodology

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/glg2x6/renal_fibrosis

Renal Fibrosis Pipeline Highlights – 2017 – Research and Markets

Submit the press release

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the „Renal Fibrosis Pipeline Highlights – 2017” drug pipelines to their offering.

This report, Renal Fibrosis Pipeline Highlights – 2017, provides most up-to-date information on key pipeline products in the global Renal Fibrosis market. It covers emerging therapies for Renal Fibrosis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Renal Fibrosis pipeline products by clinical trial stages including both early and late stage development – phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Renal Fibrosis pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Renal Fibrosis pipeline products by the company.

Short-term Launch Highlights:

Find out which Renal Fibrosis pipeline products will be launched in the US and Ex-US till 2020.

Summary:

  • Renal Fibrosis phase 3 clinical trial pipeline products
  • Renal Fibrosis phase 2 clinical trial pipeline products
  • Renal Fibrosis phase 1 clinical trial pipeline products
  • Renal Fibrosis preclinical research pipeline products
  • Renal Fibrosis discovery stage pipeline products
  • Renal Fibrosis pipeline products short-term launch highlights

Key Topics Covered:

1. Renal Fibrosis Pipeline by Stages

2. Renal Fibrosis Pipeline by Drug Class

3. Renal Fibrosis Pipeline by Company

4. Renal Fibrosis Phase 3 Clinical Trial Insights

5. Renal Fibrosis Phase 2 Clinical Trial Insights

6. Renal Fibrosis Phase 1 Clinical Trial Insights

7. Renal Fibrosis Preclinical Research Insights

8. Renal Fibrosis Discovery Stage Insights

9. Appendix

10. Research Methodology

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/glg2x6/renal_fibrosis

Muscle Spasticity Pipeline Highlights – 2017 – Research and Markets

Submit the press release

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the „Muscle Spasticity Pipeline Highlights – 2017” drug pipelines to their offering.

This report, Muscle Spasticity Pipeline Highlights – 2017, provides most up-to-date information on key pipeline products in the global Muscle Spasticity market. It covers emerging therapies for Muscle Spasticity in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Muscle Spasticity pipeline products by clinical trial stages including both early and late stage development – phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Muscle Spasticity pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Muscle Spasticity pipeline products by the company.

Short-term Launch Highlights:

Find out which Muscle Spasticity pipeline products will be launched in the US and Ex-US till 2020.

Summary:

  • Muscle Spasticity phase 3 clinical trial pipeline products
  • Muscle Spasticity phase 2 clinical trial pipeline products
  • Muscle Spasticity phase 1 clinical trial pipeline products
  • Muscle Spasticity preclinical research pipeline products
  • Muscle Spasticity discovery stage pipeline products
  • Muscle Spasticity pipeline products short-term launch highlights

Key Topics Covered:

1. Muscle Spasticity Pipeline by Stages

2. Muscle Spasticity Pipeline by Drug Class

3. Muscle Spasticity Pipeline by Company

4. Muscle Spasticity Phase 3 Clinical Trial Insights

5. Muscle Spasticity Phase 2 Clinical Trial Insights

6. Muscle Spasticity Phase 1 Clinical Trial Insights

7. Muscle Spasticity Preclinical Research Insights

8. Muscle Spasticity Discovery Stage Insights

9. Appendix

10. Research Methodology

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/8xqkmz/muscle_spasticity

Cervical Dysplasia Pipeline Highlights – 2017 – Research and Markets

Submit the press release

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the „Cervical Dysplasia Pipeline Highlights – 2017” drug pipelines to their offering.

This report, Cervical Dysplasia Pipeline Highlights – 2017, provides most up-to-date information on key pipeline products in the global Cervical Dysplasia market. It covers emerging therapies for Cervical Dysplasia in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Cervical Dysplasia pipeline products by clinical trial stages including both early and late stage development – phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Cervical Dysplasia pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Cervical Dysplasia pipeline products by the company.

Short-term Launch Highlights:

Find out which Cervical Dysplasia pipeline products will be launched in the US and Ex-US till 2020.

Summary:

  • Cervical Dysplasia phase 3 clinical trial pipeline products
  • Cervical Dysplasia phase 2 clinical trial pipeline products
  • Cervical Dysplasia phase 1 clinical trial pipeline products
  • Cervical Dysplasia preclinical research pipeline products
  • Cervical Dysplasia discovery stage pipeline products
  • Cervical Dysplasia pipeline products short-term launch highlights

Key Topics Covered:

1. Cervical Dysplasia Pipeline by Stages

2. Cervical Dysplasia Pipeline by Drug Class

3. Cervical Dysplasia Pipeline by Company

4. Cervical Dysplasia Phase 3 Clinical Trial Insights

5. Cervical Dysplasia Phase 2 Clinical Trial Insights

6. Cervical Dysplasia Phase 1 Clinical Trial Insights

7. Cervical Dysplasia Preclinical Research Insights

8. Cervical Dysplasia Discovery Stage Insights

9. Appendix

10. Research Methodology

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/b9ld7f/cervical

Global Data Center Rack PDU Market by Manufacturers, Regions, Type and Application, Forecast To 2021

Submit the press release

Data Center Rack PDU Market research report provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. Data Center Rack PDU Market is used to supply power to a server rack. Rack-mounted PDUs are available in different sizes and configurations. These traits depend on the type of connection and voltage each unit requires to function.

Analysts forecast the global Data Center Rack PDU Warming Devices market to grow at a CAGR of 6.78% during the period 2017-2021.PDUs are classified based on functionalities, including power filtering, remote monitoring, control by local area network (LAN) or simple network management protocol (SNMP), and intelligent load balancing. They are easy to install, configure, and manage. Data Center Rack PDU Market report 2017-2021 focuses on the major drivers and restraints for the key players. The Data Center Rack PDU Market research report is a professional and in-depth study on the current state of Data Center Rack PDU Warming Devices Market.

Browse more detail information about Data Center Rack PDU Market Report at: http://www.absolutereports.com/global-data-center-rack-pdu-market-2017-2021-10533716  

The research report covers the present scenario and the growth prospects of the global Data Center Rack PDU industry for 2017-2021.

The report covers the present scenario and the growth prospects of the global data center rack power distribution unit market for 2017-2021. To calculate the market size, the report considers the revenue generated from worldwide sales of data center rack PDUs.

Key Vendors of Data Center Rack PDU Market:

  • CyberPower Systems
  • Eaton
  • Vertiv
  • Legrand (Raritan)
  • Schneider Electric
  • Server Technology
  • Tripp Lite

Other prominent vendors

Get a PDF Sample of Data Center Rack PDU Market Research Report at: http://www.absolutereports.com/enquiry/request-sample/10533716  

The Data Center Rack PDU Market report also presents the vendor landscape and a corresponding detailed analysis of the major vendors operating in the market. Data Center Rack PDU Market report analyses the market potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, and market demand and supply scenarios.

Data Center Rack PDU Market Driver:

  • Increased demand for data centers
  • For a full, detailed list, view our report

Data Center Rack PDU Market Challenge:

  • Rise in complexity of data center designs
  • For a full, detailed list, view our report

Data Center Rack PDU Market Trend:

  • Use of DC power in data center
  • For a full, detailed list, view our report

Purchase report @ http://www.absolutereports.com/purchase/10533716  

 

Geographical Segmentation Of Data Center Rack PDU Market:

  • Data Center Rack PDU Market in Americas
  • Data Center Rack PDU Market in APAC
  • Data Center Rack PDU Market in EMEA

 

The report provides a basic overview of the Data Center Rack PDU industry including definitions, segmentation, applications, key vendors, market drivers and market challenges. The Data Center Rack PDU Market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status

Through the statistical analysis, the report depicts the global Data Center Rack PDU Market including capacity, production, production value, cost/profit, supply/demand and import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

Have any query? ask our expert @ http://www.absolutereports.com/enquiry/pre-order-enquiry/10533716

Key questions answered in Data Center Rack PDU Market report:

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Get Discount on Data Center Rack PDU Market Research Report at: http://www.absolutereports.com/enquiry/request-discount/10533716  

List of Exhibits in Data Center Rack PDU Market report:

  • Exhibit 01: Product offerings
  • Exhibit 02: Impact of drivers
  • Exhibit 03: Impact of drivers and challenges
  • Exhibit 04: Key countries in each region
  • Exhibit 05: Global Data Center Rack PDU Market shares by geographies 2017
  • Exhibit 06: Global Data Center Rack PDU Market shares by geographies 2021
  • Exhibit 07: Geographical segmentation by revenue 2017

And continued….

About Absolute Report:

Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.

Contact–

Mr. Ameya Pingaley

Absolute Reports

+1-408 520 9750

Email – sales@absolutereports.com

 

www.absolutereports.com

 

Takeda figure parmi les 100 entreprises les plus durables au monde pour la deuxième année consécutive

Submit the press release

OSAKA, Japon–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited [TOKYO : 4502], (« Takeda ») est fière d’avoir été classée par Corporate Knights dans l’Index 2017 Global 100 des entreprises les plus durables au monde. Takeda obtient pour la deuxième année consécutive cette distinction qui est basée sur 14 indicateurs de performance clé, y compris la productivité énergétique, la capacité d’innovation, la performance en matière de sécurité et la diversité du leadership.

L’engagement de Takeda à améliorer le futur des soins de santé remonte à 1781. Son inclusion dans l’Indice Global 100 fait ressortir les progrès réalisés par Takeda dans ses initiatives de responsabilité sociale et sa planification de la durabilité.

« La société Takeda est honorée de figurer encore une fois parmi des entreprises mondiales aussi prestigieuses », a déclaré Haruhiko Hirate, chargé des communications d’entreprise et des affaires publiques. « Pour Takeda, la responsabilité sociale de l’entreprise (RSE) consiste à mettre le patient au centre de tout ce que nous faisons. Alors que nous cherchons constamment à améliorer nos processus d’affaires, nous sommes également fiers de nous engager dans des activités promouvant une société durable et reflétant notre engagement à être une bonne entreprise citoyenne. »

Dans l’exercice de ses activités, Takeda adhère à des directives internationalement reconnues telles que les 10 principes du Pacte Mondial des Nations Unies, et à des objectifs internationaux à long terme tels que les Objectifs de développement durable (ODD).

À propos de Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited est une société pharmaceutique mondiale axée sur la R&D dont la mission est d’améliorer la santé et l’avenir des patients en traduisant la science en médicaments transformateurs. Takeda concentre ses efforts de R&D sur les domaines thérapeutiques de l’oncologie, de la gastroentérologie et du système nerveux central ainsi que sur les vaccins. Les activités de R&D de Takeda ont lieu à la fois en interne et avec des partenaires, l’objectif de la société étant de se maintenir à l’avant-garde de l’innovation. De nouveaux produits innovants, notamment en oncologie et en gastroentérologie, ainsi que sa présence sur des marchés émergents, stimulent la croissance de Takeda. Les plus de 30 000 employés de Takeda se sont engagés à améliorer la qualité de vie des patients en collaborant avec les partenaires de la société travaillant dans le secteur des soins de santé et basés dans plus de 70 pays. Pour en savoir plus, visitez http://www.takeda.com/news.

Un complément d’information sur Takeda est disponible dans son CSR Data Book 2016, http://www.takeda.com/csr/reports/.

Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.

Takeda Es Reconocida como Una de las 100 Corporaciones Más Sostenibles del Mundo por Segundo Año Consecutivo

Submit the press release

OSAKA, Japón–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited [TOKYO: 4502], („Takeda”) se enorgullece de ser nombrada por Corporate Knights en las Corporaciones Más Sostenibles del Mundo de 2017 en el Índice Mundial. Takeda logró esta distinción por segundo año consecutivo y se basa en 14 indicadores clave de desempeño, que incluyen la productividad energética, la capacidad de innovación, el desempeño de la seguridad y la diversidad de liderazgo.

Desde 1781, Takeda se ha comprometido a mejorar el futuro de la atención médica. La inclusión en el Índice Global 100 resalta el progreso que Takeda ha logrado en sus esfuerzos de responsabilidad corporativa y planificación de sostenibilidad.

„Takeda tiene el honor de ser incluida nuevamente entre estas distinguidas corporaciones globales”, señaló Haruhiko Hirate, Director de Asuntos Públicos y Comunicaciones Corporativas. „Para Takeda, la responsabilidad social corporativa (corporate social responsibility, CSR) tiene sus raíces en colocar al paciente en el centro de todo lo que hacemos. Si bien nos esforzamos continuamente por mejorar nuestros procesos comerciales, también nos enorgullecemos de participar en actividades que promueven una sociedad sostenible y que reflejen nuestro compromiso de ser un buen ciudadano corporativo”.

Al realizar sus actividades, Takeda se adhiere a las directrices reconocidas internacionalmente, como los 10 principios del Pacto Mundial de las Naciones Unidas, y los objetivos internacionales a largo plazo, como los Objetivos de Desarrollo Sostenible (Sustainable Development Goals, SDG).

Acerca de Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited es una empresa farmacéutica a nivel mundial impulsada por Investigación y Desarrollo, que asume el compromiso de brindar una mejor salud y un futuro más próspero a sus pacientes al traducir la ciencia en medicamentos que cambian la vida. Takeda concentra sus esfuerzos de R&D en las áreas terapéuticas de oncología, gastroenterología y el sistema nervioso central, y también en las vacunas. Takeda lleva a cabo R&D a nivel interno y con sus socios para mantenerse a la vanguardia de la innovación. Los productos nuevos e innovadores, especialmente en oncología y gastroenterología, como así también nuestra presencia en los mercados emergentes, impulsan el crecimiento de Takeda. Más de 30 000 empleados de Takeda asumen el compromiso de mejorar la calidad de vida de los pacientes, al trabajar con nuestros socios en la atención de la salud en más de 70 países. Para obtener más información, visite http://www.takeda.com/news.

La información adicional acerca de Takeda está disponible en su CSR Data Book 2016, http://www.takeda.com/csr/reports/.

El texto original en el idioma fuente de este comunicado es la versión oficial autorizada. Las traducciones solo se suministran como adaptación y deben cotejarse con el texto en el idioma fuente, que es la única versión del texto que tendrá un efecto legal.